Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | Starlite/ChEMBL | References |
Homo sapiens | prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Cathepsin B precursor | 0.0439 | 0.0676 | 0.5 |
Giardia lamblia | Cathepsin B precursor | 0.0439 | 0.0676 | 0.5 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.1331 | 0.2898 | 0.2898 |
Plasmodium falciparum | plasmepsin V | 0.0168 | 0 | 0.5 |
Trichomonas vaginalis | Clan CA, family C1, cathepsin B-like cysteine peptidase | 0.0439 | 0.0676 | 1 |
Giardia lamblia | Cathepsin B precursor | 0.0439 | 0.0676 | 0.5 |
Plasmodium vivax | aspartyl protease, putative | 0.0168 | 0 | 0.5 |
Echinococcus multilocularis | cathepsin b | 0.1331 | 0.2898 | 1 |
Plasmodium falciparum | plasmepsin VIII, putative | 0.0168 | 0 | 0.5 |
Plasmodium vivax | plasmepsin IV, putative | 0.0168 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin III | 0.0168 | 0 | 0.5 |
Leishmania major | cysteine peptidase C (CPC),CPC cysteine peptidase, Clan CA, family C1, Cathepsin B-like | 0.0439 | 0.0676 | 0.5 |
Plasmodium vivax | aspartyl protease, putative | 0.0168 | 0 | 0.5 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0168 | 0 | 0.5 |
Schistosoma mansoni | SmCB2 peptidase (C01 family) | 0.1331 | 0.2898 | 0.2898 |
Plasmodium vivax | plasmepsin V, putative | 0.0168 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin II | 0.0168 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin I | 0.0168 | 0 | 0.5 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0168 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin X | 0.0168 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin IX | 0.0168 | 0 | 0.5 |
Trypanosoma brucei | cysteine peptidase C (CPC) | 0.0439 | 0.0676 | 0.5 |
Onchocerca volvulus | 0.0168 | 0 | 0.5 | |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.1331 | 0.2898 | 0.2898 |
Plasmodium falciparum | plasmepsin VII | 0.0168 | 0 | 0.5 |
Brugia malayi | cathepsin B-like cysteine proteinase | 0.1331 | 0.2898 | 1 |
Plasmodium falciparum | plasmepsin VI | 0.0168 | 0 | 0.5 |
Trypanosoma cruzi | cysteine peptidase C (CPC), putative | 0.1331 | 0.2898 | 1 |
Toxoplasma gondii | cathepsin B | 0.0439 | 0.0676 | 1 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.1331 | 0.2898 | 0.2898 |
Echinococcus granulosus | cathepsin b | 0.1331 | 0.2898 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1331 | 0.2898 | 1 |
Echinococcus granulosus | cathepsin b | 0.1331 | 0.2898 | 1 |
Echinococcus multilocularis | cathepsin b | 0.1331 | 0.2898 | 1 |
Loa Loa (eye worm) | cathepsin B | 0.0439 | 0.0676 | 0.2333 |
Plasmodium vivax | aspartyl protease, putative | 0.0168 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin IV | 0.0168 | 0 | 0.5 |
Onchocerca volvulus | 0.0168 | 0 | 0.5 | |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0439 | 0.0676 | 0.0676 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 5.8 uM | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production | ChEMBL. | 17994684 |
IC50 (binding) | = 5.8 uM | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production | ChEMBL. | 17994684 |
IC50 (binding) | = 15.9 uM | Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production | ChEMBL. | 17994684 |
IC50 (binding) | = 15.9 uM | Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production | ChEMBL. | 17994684 |
Inhibition (binding) | = 0 % | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 100 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 0 % | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 100 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 3 % | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 30 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 3 % | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 30 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 13 % | Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 100 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 13 % | Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 100 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 25 % | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 10 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 25 % | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 10 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 41 % | Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 30 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 41 % | Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 30 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 70 % | Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 10 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 70 % | Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 10 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 72 % | Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 3 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 72 % | Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 3 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 79 % | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 3 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 79 % | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 3 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 90 % | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 1 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 90 % | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 1 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 92 % | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 0.3 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 92 % | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 0.3 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 98 % | Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 1 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 98 % | Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 1 uM relative to control | ChEMBL. | 17994684 |
Ratio IC50 (binding) | = 2.7 | Selectivity for human COX2 over human COX1 | ChEMBL. | 17994684 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.